Ranolazine

Research use only, not for human use.

Ranolazine is a calcium uptake inhibitor via the sodium/calcium channel, used to treat chronic angina.

Ranolazine is a calcium uptake inhibitor via the sodium/calcium channel, used to treat chronic angina. It affects the sodium-dependent calcium channels during myocardial ischemia in rabbits by altering the intracellular sodium level.(In Vivo):Ranolazine (Bolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection; for 145 minutes; male Wistar rats) treatment significantly reduces infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion.

——

Ranolazine (Bolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection; for 145 minutes; male Wistar rats) treatment significantly reduces infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion. Animal Model:Male Wistar rats (240-350 g) Dosage:Bolus injection 10 mg/kg and infusion (9.6 mg/kg/h) Administration:Bolus injection; for 145 minutes Result: Significantly reduced infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion.

CVT 303 | RS 43285-003

Others

Other Targets

Calcium Channel

Cardiovascular Disease

——

95635-55-5

427.54

C24H33N3O4

>98% (HPLC)

DMSO : 125 mg/mL 292.37 mM

COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1

——

(-20℃)

With Ice Pack

≥ 2 years